Why Quest Diagnostics Incorporated (DGX) stock moved
Quest Diagnostics Incorporated (DGX) shares rose 1.7% to $230.81 as of October 8, 2026, a modest gain from the prior close of $227.06. BestStocks flagged the session as a major change for DGX. The move is tied to a new SEC filing. Below, we break down what changed for DGX, why it matters for investors, how the stock reacted, and the catalysts on the calendar.
SEC Filing
Quest Diagnostics Incorporated (DGX) filed a new 8-K on October 6, 2026. The filing contents were not specified in available sources. Review the full 8-K filing details and monitor DGX's October 20, 2026 earnings report against the $2.85 consensus estimate.
What it means for Quest Diagnostics Incorporated investors
For Quest Diagnostics Incorporated investors, the recent signals are mixed, leaving the near-term picture neutral / mixed. On the constructive side: Material positive event; Positive 1.7% session move. Weighing against that: Quest Diagnostics fell 2.01% to $227.56 after CMS announced preliminary 2027 lab fee rules that aim to cut Medicare payments by up to $1 billion annually, with reductions phasing in through 2029 and capped at 15% per year (web_catalyst); Quest Diagnostics Incorporated moved -4.44% intraday from $244.88 to $234.00. Wall Street's consensus price target sits at $250.00, implying +8.3% upside from $230.81. BestStocks rates the overall signal quality low (49/100). With earnings roughly 14 days out, the next report is the most likely near-term test of the move.
DGX price reaction
DGX last traded at $230.81, up $3.75 (+1.65%) from the previous close of $227.06. The session traded on 0.9× average volume (below avg), so participation was unremarkable. Over the past month the stock has ranged between $227.06 and $247.45, and it currently sits about 18% of the way up that band.
Bullish and bearish analyst opinions on Quest Diagnostics Incorporated (DGX)
The consensus analyst price target on Quest Diagnostics Incorporated (DGX) is $250.00, 8.3% above the recent $230.81. Over the past 90 days analysts logged 0 upgrades, 10 maintains, and 0 downgrades. Here is how the bullish and bearish cases on DGX line up.
The bullish case
- Wall Street's consensus price target of $250.00 implies +8.3% upside from $230.81.
- The Street's most bullish target is $260.00 (+12.6%).
- Material positive event.
- Positive 1.7% session move.
- Quest Diagnostics Incorporated (DGX) moved +3.79% from $201.77 to $209.41 on July 16, 2026.
The bearish case
- The most bearish analyst target is $225.00 (-2.5%).
- Quest Diagnostics fell 2.01% to $227.56 after CMS announced preliminary 2027 lab fee rules that aim to cut Medicare payments by up to $1 billion annually, with reductions phasing in through 2029 and capped at 15% per year (web_catalyst).
- Quest Diagnostics Incorporated moved -4.44% intraday from $244.88 to $234.00.
Weighing both sides, BestStocks' composite read of recent signals is roughly balanced, as the bull-versus-bear meter above shows. This is an educational summary of the bull and bear case, not investment advice.
Analyst price targets and ratings are FMP consensus figures as of Oct 8, 2026; other aggregators may differ. High and low targets show the range of estimates, not forecasts.
Previous notable changes for DGX
In-depth DGX event analyses
Frequently asked questions about DGX
Why did Quest Diagnostics Incorporated (DGX) stock move?
DGX rose 1.7% to $230.81. The move is associated with a new SEC filing.
How much did DGX stock rise?
DGX gained 1.65% ($3.75) versus the prior close of $227.06, last trading at $230.81 on 0.9× average volume.
When is Quest Diagnostics Incorporated's next earnings date?
DGX's next earnings report is estimated for 2026-10-22 — about 14 days away.
What is the analyst price target for DGX?
The consensus analyst price target for DGX is $250.00, about 8.3% above the current $230.81. Over the past 90 days, analysts recorded 0 upgrades, 10 maintains, and 0 downgrades.
How BestStocks tracks DGX
This page is generated automatically by BestStocks' change-detection system after a new SEC filing was detected and verified against independent data sources. It draws on 20 tracked change events for DGX, cross-checked against the data sources listed below. Price, volume, and market-capitalization figures are the live intraday quote as of October 8, 2026 and refresh as new information is detected; for companies with multiple share classes, market-cap figures can differ by data source. Analyst price targets and ratings are FMP consensus. This is an educational summary of what changed and why — not personalized investment advice.